Inverse relationship between Skp2 ubiquitin ligase and the cyclin dependent kinase inhibitor p27Kip1 in prostate cancer

Journal of Urology

Volumn 170, Issue 1, 2003, Pages 241-245

  Ben Izhak, Ofer ^a   Lahav Baratz, Shirly ^a   Meretyk, Shimon ^a   Ben Eliezer, Shoshana ^a   Sabo, Edmond ^a   Dirnfeld, Martha ^a   Cohen, Shai ^a   Ciechanover, Aaron ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

Biopsy; Cyclin dependent kinases; Prostate; Prostatic neoplasms; Ubiquitin

Indexed keywords

CYCLIN DEPENDENT KINASE INHIBITOR; KI 67 ANTIGEN; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27; S PHASE KINASE ASSOCIATED PROTEIN 2; UBIQUITIN PROTEIN LIGASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER GRADING; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOFLUORESCENCE MICROSCOPY; IMMUNOHISTOCHEMISTRY; MALE; METASTASIS; MOLECULAR RECOGNITION; NEEDLE BIOPSY; PATHOGENESIS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE TUMOR; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; WESTERN BLOTTING;

EID: 0038679293     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ju.0000072113.34524.a7     Document Type: Article

References (12)

1. Sherr, C. J. and Roberts, J. M.: CDK inhibitors: positive and negative regulators of G1-phase progression. Genes Dev, 13: 1501, 1999
2. Glickman, M. H. and Ciechanover, A.: The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. Physiol Rev, 82: 373, 2002
3. Carrano, A. C., Eytan, E., Hershko, A. and Pagano, M.: SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27. Nat Cell Biol, 1: 193, 1999
4. Deshaies, R. J.: SCF and Cullin/Ring H2-based ubiquitin ligases. Annu Rev Cell Dev Biol, 15: 435, 1999
5. Tsihlias, J., Kapusta, L. and Slingerland, J.: The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer. Annu Rev Med, 50: 401, 1999
6. Tan, P., Cady, B., Wanner, M., Worland, P., Cukor, B., Magi-Galluzzi, C. et al: The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res, 57: 1259, 1997
7. Loda, M., Cukor, B., Tam, S. W., Lavin, P., Fiorentino, M., Draetta, G. F. et al: Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med, 3: 231, 1997
8. Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res, 58: 542, 1998
9. Thomas, G. V., Schrage, M. I., Rosenfelt, L., Kim, J. H., Salur, G., deKernion, J. B. et al: Preoperative prostate needle biopsy p27 correlates with subsequent radical prostatectomy p27, Gleason grade and pathological stage. J Urol, 164: 1987, 2000
10. Hershko, D., Bornstein, G., Ben-Izhak, O., Carrano, A., Pagano, M., Krausz, M. M. et al: Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas. Cancer, 91: 1745, 2001
11. Guo, Y., Sklar, G. N., Borkowski, A. and Kyprianou, N.: Loss of the cyclin-dependent kinase inhibitor p27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res, 3: 2269, 1997
12. Yang, R. M., Naitoh, J., Murphy, M., Wang, H.-J., Phillipson, J., deKernion, J. B. et al: Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol, 159: 941, 1998